

## I. AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:


Claims 1 – 55. (Canceled).

56. (Currently Amended) A method for inhibiting the proliferation of a hyperproliferative neoplastic cell that endogenously overexpresses thymidylate synthase, comprising contacting the cell with a compound of claim 62 ~~or a 5'-monophosphate metabolite thereof formed after administration to a subject.~~

57. (Currently Amended) A method for treating a pathology characterized by hyperproliferative neoplastic cells that endogenously ~~overexpresses~~ overexpress thymidylate synthase in a subject comprising administering to the subject a compound of claim 62 ~~or a 5'-monophosphate metabolite thereof formed after administration to a subject.~~

58. (Canceled).


59. (Previously Presented) The method of claim 56 or 57, wherein Q has the formula:



60. (Previously Presented) The method of claim 56 or 57, wherein  $R_1$  is a halogen.


61. (Previously Presented) The method of claim 56 or 57, wherein  $R_1$  is of the formula  $(-CH=CH)_n-R_4$ , wherein  $n$  is an integer from 1 to 10, and  $R_4$  is selected from the group consisting of H; hydroxyl; a halogen;  $-NHCHO$ ;  $-OCN$ ;  $-SCN$ ;  $-N_3$ ;  $-NH_2$ ;  $-NHOH$ ;  $-NHNH_2$  and a  $C_2$  to  $C_4$  carbon-containing substituent selected from the group consisting of alkyl, alkenyl, alkynyl,  $-O$ -alkyl,  $-O$ -aryl,  $O$ -heteroaryl,  $-S$ -alkyl,  $-S$ -aryl,  $-S$ -heteroaryl,  $-NH$ -alkyl,  $-N(alkyl)_2$  and  $NHO$ -alkyl.

62. (Currently Amended) A compound of the formula:



wherein:

$R^1$  is of the formula:




wherein  $R^2$  is one of:

an unsaturated  $C_2$  to  $C_4$  hydrocarbyl group;


or

a heteroaromatic group having the structure:



wherein J is -O-, -S-, -Se-, -NH-, or -NR<sup>ALK</sup>-, wherein R<sup>ALK</sup> is a linear or branched alkyl having 1 to 10 carbon atoms or a cycloalkyl group having 3 to 10 carbon atoms;

R<sup>3</sup> is selected from the group consisting of:







wherein R<sup>5</sup> may be the same or different and is independently a linear or branched alkyl group having from 1 to 10 carbon atoms, or a cycloalkyl group having from 3 to 10 carbon atoms;


wherein n is an integer from 1 to 10;

wherein m is 0 or 1;

wherein R<sup>4</sup> is a toxophore selected from the group consisting of:



and




wherein X is -Cl, -Br, -I, or other halogen, with the proviso that when R<sup>7</sup> is -H, and m is zero, then R<sup>4</sup> is not a halogen or when m is zero and n is zero, then R<sup>4</sup> is not a halogen;

wherein Y is independently -H or -F;

wherein Z is independently -O- or -S-;

wherein Q is selected from the group consisting of:




wherein  $R^6$  is independently -H, -OH, -OC(=O)CH<sub>3</sub>, or -O- $R_9$  wherein  $R_9$  is a hydroxyl protecting group other than acetyl; and,


wherein  $R^7$  is hydrogen, a phosphoryl derivative or a phosphoramidatyl derivative of a naturally-occurring amino acid;

and wherein said compound may be in any enantiomeric, diastereomeric, or stereoisomeric form, ~~consisting of a D-form, L-form,  $\alpha$ -anomeric form, and  $\beta$ -anomeric form~~ or stereoisomeric form, wherein the stereoisomeric form consists of a D-form and an L-form.


63. (Currently Amended) A compound according to claim 62, wherein Q is:




64. (Previously Presented) A compound of claim 62, wherein  $R^3$  is selected from the group consisting of:



65. (Previously Presented) A compound of claim 62, wherein  $R^2$  is selected from the group consisting of:




66. (Previously Presented) A compound of claim 62, wherein  $R^2$  and  $R^3$ , taken together form a structure selected from the group consisting of:




67. (Canceled).

68. (Canceled).

69. (Previously Presented) A compound of claim 62, wherein R<sup>7</sup> is:




70. (Previously Presented) A compound of claim 62, wherein R<sup>7</sup> is:



71. (Canceled).

72. (Canceled).


73. (Original) A compound of claim 62, wherein R<sup>4</sup> is selected from the group consisting of:




74. (Original) A compound of claim 62, wherein R<sup>4</sup> is selected from the group consisting of:







75. (Original) A compound of claim 62, wherein  $R^4$  is:



76. (Previously Presented) A compound of claim 62, wherein  $R^4$  is:




77. (Previously Presented) A compound of claim 62, wherein  $R^4$  is:






78. (Original) A compound of claim 62, wherein R<sup>4</sup> is:



79. (Original) A compound of claim 62, wherein R<sup>4</sup> is:




Claims 80-87. (Canceled).

88. (Currently Amended) The method of claims 56 or 57, wherein the hyperproliferative cell is a cancer cell selected from the group consisting of a colorectal cell and a breast cancer cell.

89. (Canceled)

90. (New) The compound of claim 62, wherein R<sup>7</sup> is a phosphoryl derivative selected from the group consisting of:



where R is an aromatic substituent.